Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

311 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Site-specific Response to Nivolumab in Renal Cell Carcinoma.
Negishi T, Furubayashi N, Nakagawa T, Nishiyama N, Kitamura H, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, Okajima E, Nakamura M. Negishi T, et al. Among authors: tomoda t. Anticancer Res. 2021 Mar;41(3):1539-1545. doi: 10.21873/anticanres.14913. Anticancer Res. 2021. PMID: 33788747
The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Tamura S, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Among authors: tomoda t. Cancer Manag Res. 2021 Oct 24;13:8049-8056. doi: 10.2147/CMAR.S333823. eCollection 2021. Cancer Manag Res. 2021. PMID: 34729023 Free PMC article.
Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, Miura A, Komori H, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Among authors: tomoda t. Cancer Manag Res. 2022 May 3;14:1641-1651. doi: 10.2147/CMAR.S360473. eCollection 2022. Cancer Manag Res. 2022. PMID: 35535266 Free PMC article.
Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Harada M, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Tamura S, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: tomoda t. Clin Genitourin Cancer. 2022 Oct;20(5):499.e1-499.e8. doi: 10.1016/j.clgc.2022.05.001. Epub 2022 May 5. Clin Genitourin Cancer. 2022. PMID: 35624001
The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Harada M, Tamura S, Kobayashi H, Wada Y, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Among authors: tomoda t. Onco Targets Ther. 2022 Nov 5;15:1321-1330. doi: 10.2147/OTT.S389138. eCollection 2022. Onco Targets Ther. 2022. PMID: 36388155 Free PMC article.
Early Phase Persistent Changes in the White Blood Cell Fraction in Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab: A Multicenter Retrospective Study.
Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Masaoka H, Harada M, Tamura S, Kobayashi H, Morihara K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M. Furubayashi N, et al. Among authors: tomoda t. Anticancer Res. 2023 Oct;43(10):4701-4708. doi: 10.21873/anticanres.16666. Anticancer Res. 2023. PMID: 37772560
311 results